GlobeNewsWire - NOVO NORDISK A/S (NOVO B) Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

NOVO B NOVO NORDISK A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 1 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyveled
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	2,028 shares


d)	Aggregated information Aggregated volume Price	2,028 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyveled
2	Reason for the notification
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	2,042 shares


d)	Aggregated information Aggregated volume Price	2,042 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	131,760 shares


d)	Aggregated information Aggregated volume Price	131,760 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	149,422 shares


d)	Aggregated information Aggregated volume Price	149,422 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	41,488 shares


d)	Aggregated information Aggregated volume Price	41,488 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	48,791 shares


d)	Aggregated information Aggregated volume Price	48,791 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	2,166 shares


d)	Aggregated information Aggregated volume Price	2,166 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	2,548 shares


d)	Aggregated information Aggregated volume Price	2,548 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	37,346 shares


d)	Aggregated information Aggregated volume Price	37,346 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	36,664 shares


d)	Aggregated information Aggregated volume Price	36,664 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	11,620 shares


d)	Aggregated information Aggregated volume Price	11,620 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	11,407 shares


d)	Aggregated information Aggregated volume Price	11,407 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	41,254 shares


d)	Aggregated information Aggregated volume Price	41,254 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	43,402 shares


d)	Aggregated information Aggregated volume Price	43,402 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	41,488 shares


d)	Aggregated information Aggregated volume Price	41,488 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	39,755 shares


d)	Aggregated information Aggregated volume Price	39,755 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	22,027 shares


d)	Aggregated information Aggregated volume Price	22,027 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	19,878 shares


d)	Aggregated information Aggregated volume Price	19,878 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President, head of North America Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	ADRs
	Identification code	NVO
b)	Nature of the transaction	Purchase of ADRs
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 1,092.25	16.31 ADRs


d)	Aggregated information Aggregated volume Price	16.31 ADRs DKK 1,092.25
e)	Date of the transaction	2023-04-10
f)	Place of the transaction	New York Stock Exchange

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification
a)	Position/status	Executive Vice President, head of North America Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	ADRs
	Identification code	NVO
b)	Nature of the transaction	Purchase of ADRs
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 1,275.49	10.42 ADRs


d)	Aggregated information Aggregated volume Price	10.42 ADRs DKK 1,275.49
e)	Date of the transaction	2023-09-01
f)	Place of the transaction	New York Stock Exchange

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	16,780 shares


d)	Aggregated information Aggregated volume Price	16,780 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	33,600 shares


d)	Aggregated information Aggregated volume Price	33,600 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	7,763 shares


d)	Aggregated information Aggregated volume Price	7,763 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	13,220 shares


d)	Aggregated information Aggregated volume Price	13,220 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	413 shares


d)	Aggregated information Aggregated volume Price	413 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 756.84	702 shares


d)	Aggregated information Aggregated volume Price	702 shares DKK 756.84
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Nasdaq Copenhagen

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	16,780 shares


d)	Aggregated information Aggregated volume Price	16,780 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	33,600 shares


d)	Aggregated information Aggregated volume Price	33,600 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	41,254 shares


d)	Aggregated information Aggregated volume Price	41,254 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	43,402 shares


d)	Aggregated information Aggregated volume Price	43,402 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	43,563 shares


d)	Aggregated information Aggregated volume Price	43,563 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			DKK 0.00	45,834 shares


d)	Aggregated information Aggregated volume Price	45,834 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit , , , , and .

Contacts for further information

Media:
Ambre James-Brown	Elizabeth DeLuca (US)
Investors:
Daniel Muusmann Bohsen	Frederik Taylor Pitter
David Heiberg Landsted	Mark Joseph Root (US)
Sina Meyer

Company Announcement No 8 / 2024

Attachment

01/02/2024

Underlying

NOVO BNOVO NORDISK A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

PRESS RELEASE

Free

NOVO B NOVO NORDISK A/...

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 1...

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1**Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors1Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to th...

September 17, 2025 1 EN

SCHP SECHE ENVIRONNE...
BMW BAYERISCHE MOTO... ... (+47)

Daimler Truck : Sustainability Weekly 8 - 12 September 2025

Last week, we published a report in which we propose ideas on the theme of sustainable sovereignty. Technip Energies signed an agreement to acquire the Advanced Materials & Catalysts business of Ecovyst Inc, a global leader in specialty catalysts and advanced materials. The IEA is expected to reintroduce its slow transition scenario, ‘Current Policies’, in its next World Energy Outlook, probably under pressure from the Trump administration. German Chancellor Merz has hinted at a slowdown in the ...

SCHP SECHE ENVIRONNEMENT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
FP TOTAL SE
ENX EURONEXT NV
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
EDEN EDENRED SA
TKA THYSSENKRUPP AG
DG VINCI SA
MT ARCELORMITTAL SA
NK IMERYS SA
BN DANONE SA
SU SCHNEIDER ELECTRIC SE
RNO RENAULT SA
G1A GEA GROUP AG
APAML APERAM SA
HO THALES SA
FGR EIFFAGE SA
DAI DAIMLER AG
LONN LONZA GROUP AG
KOF KAUFMAN & BROAD SA
SDF K+S AG
RWE RWE AG
SOLB SOLVAY SA
NEX NEXANS SA
ERA ERAMET SA
CAP CAPGEMINI SE
ENEL ENEL SPA
WPP WPP PLC
RY4C RYANAIR HOLDINGS PLC
SOI SOITEC SA
ERG ERG S.P.A.
ANA ACCIONA SA
ELI ELIA GROUP SA/NV
IBE IBERDROLA SA
LDO LEONARDO SPA
BHP BHP GROUP LTD
ASML ASML HOLDING NV
STLA STELLANTIS N.V.
TE TECHNIP ENERGIES NV
ALAFY AFYREN
OVH OVH GROUPE
DTG DAIMLER TRUCK
DSFIR KONINKLIJKE DSM N.V.
NOVO B NOVO NORDISK A/S
EXENS EXOSENS
AAL ANGLO AMERICAN PLC

09/15/25 September 15, 2025 1 EN

SCHP SECHE ENVIRONNE...
BMW BAYERISCHE MOTO... ... (+47)

Daimler Truck : Sustainability Weekly 8 – 12 septembre 2025

La semaine passée, nous avons publié une étude où nous proposons des idées pour la thématique de la souveraineté durable. Technip a signé un accord en vue d'acquérir l'activité Advanced Materials & Catalysts d'Ecovyst Inc, leader mondial des catalyseurs spéciaux et des matériaux avancés. L'AIE devrait réintroduire son scénario de transition lente « Current Policies » dans son prochain World Energy Outlook, probablement sous la pression de l'administration Trump. Le chancelier allemand Merz a lai...

09/15/25 September 15, 2025 1 FR

Maxime Kogge ... (+2)

Maxime Kogge
Thomas Zlowodzki

ULVR UNILEVER PLC
FHZN Flughafen Zuric... ... (+8)

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 09/10/2025

ULVR UNILEVER PLC
FHZN FLUGHAFEN ZURICH AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
STM STMICROELECTRONICS NV
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PUIG PUIG BRANDS
AAL ANGLO AMERICAN PLC

09/10/25 September 10, 2025 1 EN

Maxime Kogge ... (+2)

Maxime Kogge
Thomas Zlowodzki

ULVR UNILEVER PLC
FHZN Flughafen Zuric... ... (+7)

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/09/2025

ULVR UNILEVER PLC
FHZN FLUGHAFEN ZURICH AG
STM STMICROELECTRONICS NV
NOVO B NOVO NORDISK A/S
AGN AEGON N.V.
PUIG PUIG BRANDS
AAL ANGLO AMERICAN PLC

09/10/25 September 10, 2025 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO B NOVO NORDISK A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Underlying

Reports on NOVO NORDISK A/S

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 1...

Daimler Truck : Sustainability Weekly 8 - 12 September 2025

Daimler Truck : Sustainability Weekly 8 – 12 septembre 2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 09/10/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 10/09/2025

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe